DURECT awaiting Pfizer meeting with FDA on Remoxy
DURECT (NASDAQ:DRRX) has a lot riding on a meeting in late March between its marketing partner, Pfizer, and the FDA to discuss resubmitting a new drug application for its lead pain drug, Remoxy, as a...
View ArticleElite eyes home run in abuse-resistant technology
After reinventing itself in 2011, Elite Pharmaceuticals (OTCBB:ELTP) has bounced back with a line of generic drugs and is banking on the development of abuse-resistant opioids and once-daily opioid...
View ArticleTitan implanting treatments for opioid dependence
In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a...
View ArticleTitan Pharma posts positive Phase 3 Probuphine results
Titan Pharmaceuticals (OTCQB:TTNP) has reported positive topline results from a Phase 3 double blind, double dummy clinical study of Probuphine, its subdermal implant containing buprenorphine HCl for...
View ArticleTitan Pharma Phase 3 data validate ProNeura technology
Titan Pharmaceuticals’ (OTCQB:TTNP) positive topline results from a Phase 3 clinical study of Probuphine, its subdermal implant of buprenorphine for the long-term maintenance treatment of opioid...
View Article